All In Biotech

Drug Trial Radar · NCT05844787

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics Profile of MT101-5 in Healthy Volunteers

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose (SAD) Study Including a Food Interaction Study, Followed by a Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability and Pharmacokinetics Profile of MT101-5 in Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: May 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

48

Actual

Start

Jul 11, 2022

Primary completion

Feb 23, 2023

Study completion Feb 23, 2023

Sponsor

Lead sponsor
Mthera Pharma Co., Ltd.Industry
Sponsor type
Industry
Collaborators
Amarex Clinical Research
First posted
May 6, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, care provider)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary study objective is to establish the safety and tolerability of MT101-5 after a single and multiple dose administrations in healthy volunteers. The safety and overall tolerability of MT101-5 will be evaluated based on: * Incidence of Dose Limiting Toxicities (DLTs) * Incidence of Treatment-Emergent Adverse Events (TEAEs). * Incidence of withdrawals due to Adverse Events (AEs). * Change/shifts in laboratory values. Change in vital signs. * Change in Electrocardiogram (ECG) parameters. * Changes in physical examination findings

Conditions

  • Parkinson's Disease

Interventions

  • MT101-5Drug

    Tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Dose Limiting Toxicities (DLTs)Time frame: Day 1 through 7 days after the last study drug administration
  2. Incidence of Treatment-Emergent Adverse Events (TEAEs)Time frame: Day 1 through 7 days after the last study drug administration
  3. Incidence of withdrawals due to Adverse Events (AEs)Time frame: Day 1 through 7 days after the last study drug administration
  4. Change in complete blood count testTime frame: Change from baseline to day 7 after the first study drug administration
  5. Change in comprehensive metabolic panel testTime frame: Change from baseline to day 7 after the first study drug administration
  6. Change in urinalysis testTime frame: Change from baseline to day 7 after the first study drug administration
  7. Change in pregnancy testTime frame: Change from baseline to day 7 after the first study drug administration
  8. Change of blood pressure (both systolic and diastolic blood pressures)Time frame: Change from pre-dose to 96 hours after last study drug administration
  9. Change of blood pressure (both systolic and diastolic blood pressures)Time frame: Change from pre-dose to day 7 after the last study drug administration
  10. Change of pulseTime frame: Change from pre-dose to 96 hours after last study drug administration
  11. Change of pulseTime frame: Change from pre-dose to day 7 after the last study drug administration
  12. Change of temperatureTime frame: Change from pre-dose to 96 hours after last study drug administration
  13. Change of temperatureTime frame: Change from pre-dose to day 7 after the last study drug administration
  14. Change of respiratory rateTime frame: Change from pre-dose to 96 hours after last study drug administration
  15. Change of respiratory rateTime frame: Change from pre-dose to day 7 after the last study drug administration
  16. ECG ventricular rate (beats per minute)Time frame: At pre-dose
  17. ECG ventricular rate (beats per minute)Time frame: 96 hours after study drug administration
  18. ECG ventricular rate (beats per minute)Time frame: On day 7 after the last study drug administration
  19. PR interval (msec)Time frame: At pre-dose
  20. PR interval (msec)Time frame: 96 hours after study drug administration
  21. PR interval (msec)Time frame: On day 7 after the last study drug administration
  22. QRS interval (msec)Time frame: At pre-dose
  23. QRS interval (msec)Time frame: 96 hours after study drug administration
  24. QRS interval (msec)Time frame: On day 7 after the last study drug administration
  25. QT interval (msec)Time frame: At pre-dose
  26. QT interval (msec)Time frame: 96 hours after study drug administration
  27. QT interval (msec)Time frame: On day 7 after the last study drug administration
  28. QTc interval (msec)Time frame: At pre-dose
  29. QTc interval (msec)Time frame: 96 hours after study drug administration
  30. QTc interval (msec)Time frame: On day 7 after the last study drug administration
  31. Maximum observed plasma drug concentration (Cmax)Time frame: 0-96 hours
  32. Apparent terminal elimination half-life (t1/2)Time frame: 0-96 hours
  33. Time to maximum observed plasma drug concentration (Tmax)Time frame: 0-96 hours
  34. Area under the plasma drug concentration-time curve (AUC)Time frame: 0-96 hours
  35. Percentage of AUC0-∞ extrapolated from Tlast to infinity (AUCext)Time frame: 0-96 hours
  36. Apparent plasma clearance (CL/F)Time frame: 0-96 hours
  37. Apparent Volume of distribution (Vz/F)Time frame: 0-96 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Frontage Clinical Services, 1nc.

    Secaucus, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.